analogues du glp 1 GLP-1 analogs and dual incretin agonists to support weight loss Dosage of GLP-1 analogues |
Description
Among them, retatrutide has shown significant clinical advantages in phase II clinical trials, reducing the weight of obese patients by up to 24.2% in 48 weeks and lowering the HbA1c of type 2 diabetes patients by 2.2% in 36 weeks (49, 50)
(2023) reported that semaglutide reduced both baseline and relapse-like alcohol consumption in rats, blunted ethanol-induced hyperlocomotion and NAc dopamine release, and increased expression of dopamine-metabolizing enzymes
Read on to find out about their experiences, how the medication worked and what challenges they faced
doi: 10.1042/BJ20101185
